Chloral hydrate versus midazolam for sedation of children for neuroimaging: a randomized clinical trial

Area of Science:

• Pediatric Anesthesiology
• Neuroimaging Sedation
• Pharmacological Efficacy Studies

Background:

• Comparative safety and efficacy of chloral hydrate and midazolam for pediatric sedation remain understudied.
• Effective sedation is crucial for successful pediatric neuroimaging.
• Existing data on these agents for this specific application is limited.

Purpose of the Study:

• To compare the safety and efficacy of oral chloral hydrate versus midazolam for sedating children undergoing neuroimaging.
• To evaluate success rates and need for supplemental sedation in a pediatric neuroimaging cohort.
• To assess physiological parameters during sedation with both agents.

Main Methods:

• A double-blind, randomized trial involving 40 children (2 months to 8 years) requiring sedation for outpatient neuroimaging.
• Children received either chloral hydrate (75 mg/kg) or midazolam (0.5 mg/kg) orally.
• Monitoring included vital signs, oxygen saturation, and anxiety; efficacy judged by scan completion and need for supplemental dosing.

Main Results:

• Chloral hydrate showed significantly higher efficacy (100% vs. 50%) and a lower requirement for supplemental dosing (9% vs. 55%) compared to midazolam.
• Sedation failure rate was significant overall, but markedly lower in the chloral hydrate group.
• No significant differences in sedation duration or adverse physiological events were observed; no oxygen was required.

Conclusions:

• Oral chloral hydrate at the tested dosage (75 mg/kg) appears more effective than midazolam (0.5 mg/kg) for short pediatric neuroimaging procedures.
• Chloral hydrate offers a potentially better option for achieving adequate sedation in this population.
• Further research may explore optimal dosing and long-term safety profiles.